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ACL rupture is a major risk factor for post-traumatic osteoarthritis (PTOA) development. Little 
information exists on acute systemic metabolic indicators of disease development. 36 female 
Lewis rats were randomized to Control or noninvasive anterior cruciate ligament rupture 
(ACLR) and to three post-injury time points: 72 hours, 4 weeks, 10 weeks (n=6). Serum was 
collected and analyzed by 1H nuclear magnetic resonance (NMR) spectroscopy and combined 
direct injection and liquid chromatography (LC)-mass pectrometry (MS)/MS (DI-MS). 
Univariate and multivariate statistics were used to analyze metabolomic data, and predictive 
biomarker models were analyzed by receiver operating characteristic (ROC) analysis. 
Topological pathway analysis was used to identify perturbed pathways. 222 metabolites were 
identified by 1H NMR and DI-MS. Differences in the serum metabolome between ACLR and 
Control were dominated by medium- and long-chain acylc rnitine species. Further, decreases in 
several tryptophan metabolites were either found to be significantly different in univariate 
analysis or to play important contributory roles to multivariate model separation. In addition to 
acylcarnitines and tryptophan metabolites, glycine, carnosine, and D-mannose were found to 
differentiate ACLR from Control. Glycine, 9-hexadecenoylcarnitine, trans-2-
Dodecenoylcarnitine, linoelaidyl carnitine, hydroxypropionylcarnitine, and D-Mannose were 
identified as biomarkers with high area under ROC curve values and high predictive accuracies. 
Our analysis provides new information regarding thepotential contribution of inflammatory 
processes and immune dysregulation to the onset and progression of PTOA following ACL 









arthropathies, larger-scale studies elucidating their involvement in PTOA development and 
progression are necessary. 
Keywords: Post-traumatic osteoarthritis, metabolomics, anterior cruciate ligament rupture, 
inflammation, immunity 
 INTRODUCTION 
Anterior cruciate ligament (ACL) rupture is a major risk factor for post-traumatic 
osteoarthritis (PTOA) development, and studies have demonstrated long-term incidences of 
PTOA following ACL rupture as high as 50-90% 1-4. The ACL is a major stabilizer of the knee, 
and its rupture is associated with high-energy joint trauma. This initial trauma, subsequent joint 
laxity, persistent inflammation, and non-native joint kinematics after surgical reconstruction are 
among the most commonly-proposed reasons for PTOA onset and progression 1; 2; 5; 6. 
Relatively little is known about specific biological pathways responsible for the initiation 
and progression of ACL rupture-induced PTOA. Mechanobiological responses of the synovium, 
ACL, articular cartilage, and other tissues trigger the release of pro-inflammatory cytokines, 
proteases, and extracellular matrix (ECM) products5-11, initiating what is generally accepted as an 
irreversible, degenerative cascade.1; 12 Protein- and gene-level changes in the synovium 
following ACL rupture induce chronic synovitis13, a tissue condition characteristic of PTOA, and 
the synovium is known to be a major modulator of joint inflammation and catabolism13. 
Compositional and morphological adaptation occurs in subchondral and trabecular bone 
following ACL rupture14; 15, and articular cartilage degeneration is thought to begin at the time of 
trauma, with processes responsible for chondrocyte apoptosis and altered protein expression 









attributed to the OA process, recent studies have demonstrated that both pathologic thinning and 
hypertrophic thickening occur following ACL rupture17-19, indicating dynamic, time-dependent 
processes during PTOA initiation and progression.      
Given the plethora of biological processes potentially nvolved in PTOA, a need exists 
for more sensitive characterization of disease mechanisms that may be targeted for therapeutic 
intervention or improved, earlier diagnosis. An increasing number of publications have sought to 
identify biomarkers of PTOA, with numerous potential argets identified in urine, synovial fluid, 
and serum20. Metabolomics is a promising new technology enabling comprehensive and 
concurrent system-wide profiling of multiple metabolite concentrations in response to external 
stimuli including lifestyle, diet, disease and genetic influences21. The major analytical methods 
used for high throughput metabolomics consist of 1H nuclear magnetic resonance (1H NMR) and 
mass spectrometry (usually with a chromatographic component), collectively providing 
complementary structural and conformational information on numerous compounds classes in a 
single analyses21. Data acquired via these platforms are increasingly popular, as evidenced by the 
rise in the number of studies utilizing high resoluti n metabolomics platforms to identify 
metabolites and metabolic pathways associated with PTOA and OA progression22-25. 
Most preclinical animal studies employ surgically-induced models of PTOA (e.g. surgical 
ACL transection, medial meniscal destabilization), but these models may not accurately 
recapitulate the disease process in humans. With regards to metabolomics, these models could 
introduce confounding metabolites associated with surgical trauma, precluding accurate 
characterization of the pathology. In contrast, noni vasive injury models more accurately 
reproduce high-energy joint loading and induce a closed, clinically-relevant injury, representing 









a tibial compression model to induce closed, isolated ACL rupture in the rat 26. This injury leads 
to drastic morphological tissue changes representative of PTOA 14; 17. The purpose of this pilot 
study was to employ this model in combination with high-resolution 1H NMR and MS to study 
serum-levelmetabolic changes in the acute and intermediate post-injury timeframe of PTOA 
onset and progression.  
MATERIALS AND METHODS:  
Treatment Groups, Noninvasive ACL Injury, and Specim n Collection  
Under an IACUC-approved protocol, 36 female Lewis rats aged 14 weeks, ~200 g 
(Charles River Laboratories, Wilmington, MA, USA) were acclimated to a 12-hr light/dark 
facility for one week. Using a computer algorithm, rats were randomized to a control group 
(anesthesia and analgesia only, no injury loading) or noninvasive ACL rupture (ACLR) group. 
Rats were then further randomized to three time points: 72 hours, 4 weeks, and 10 weeks (n=6 
rats per group per time point). Throughout the study, rats were allowed ad libitum cage activity 
and provided unlimited access to food and water. ACLR rats were subjected to a tibial 
compression-based noninvasive ACL rupture protocol, as previously described14; 17; 26. Briefly, 
rats were immobilized in prone position on a custom fixture on a materials testing system 
(Insight 5, MTS Systems, Eden Prairie, MN, USA). The right knee was flexed to 100° and 
constrained to restrict medial and lateral translation, and the right paw was mounted in 30° of 
dorsiflexion. After a preloading and preconditioning, a displacement of 3 mm was rapidly 
applied to the paw at a rate of 8 mm/s, causing anterior tibial subluxation and subsequent failure 
of the ACL26. Anesthesia was induced with intraperitoneal ketamine/xylazine and maintained 
with 1-2% inhaled isoflurane. Subcutaneous carprofen was administered for preemptive 









bony remodeling14, articular cartilage degeneration with documented worsening histologic grade 
(OARSI score of ~12 at 4 and 10 weeks) 17, and acute stem cell migration27 have been published 
on the same rats utilized in this study and can be ref renced for further information on 
downstream joint changes and cellular phenomena.  
At respective 72-hour, 4-week, and 10-week time points, whole blood was collected via 
cardiac puncture and rats were euthanized by CO2 asphyxia. Serum was obtained via 
centrifugation at 1,200 g at 4°C for 10 mins, aliquoted, and stored at -80°C until processing.  
1H NMR Sample preparation and data acquisition 
Serum specimens were prepared as described by Mercier t al28. Briefly, 3 KDa cut-off 
centrifugal filter units (Amicon Microcon YM-3; Sigma-Aldrich, St. Louis, MO) were rinsed 
seven times by centrifugation (12,000 g for 30 min) using 0.5 ml of H2O to remove residual 
glycerol. Subsequently, 250 µl of rat serum was transferred to the filter units and centrifuged at 
13,000 g for 30 min at 4°C. 200 µl of filtered serum was combined with 25 µl of D2O and 21 µl 
of standard buffer solution consisting of 11.7 mM DSS [disodium-2,2-dimethyl-2-silapentane-5-
sulphonate], 1.75 M K2HPO4, and 5.84 mM 2-chloro pyrimidine-5-carboxylic acid (phasing 
standard) in H2O. Using an Eppendorf liquid handler, 200 µl were transferred to 3 mm NMR 
tubes for analysis by NMR. 
All 1H-NMR experiments were recorded at 300.0 K (±0.05) using a Bruker Avance III 
HD 600 MHz spectrometer coupled with a 5 mm TCI cryoprobe (Bruker-Biospin, Billerica, MA, 
USA). Using a randomized running order, 1D 1H NMR spectra were acquired using a pulse 









DSS was used as the internal standard for chemical shift referencing and quantification. 
Collected spectra were analyzed using a custom library of 59 metabolites using Bayesil29. 
Combined Direct Injection and LC-MS/MS (DI-MS) compund identification and quantification 
 A comprehensive description of this analysis has been previously described by our group 
30. Briefly, targeted analysis was carried out using AbsoluteIDQ p180 kit (Biocrates Life 
Sciences AG, Innsbruck, Austria) on a TQ-S mass spectrometer coupled to an Acquity I Class 
ultra-pressure liquid chromatography (UPLC) system (Waters Technologies Corporation, 
Milford, MA, USA). Serum samples were analyzed using the protocol described in AboluteIDQ 
manual.  
Univariate and Multivariate Statistical Analyses 
Univariate statistical analyses of all concentration data from 1H-NMR and DI-MS were 
performed using SPSS (v22, IBM, Armonk, NY, USA). Zero values were treated as missing 
values, and features with more than 50% missing values were excluded entirely. To assess 
differences in metabolite concentrations as a functio  of experimental group and time point, two-
way analysis of variance (ANOVA) was used. Post hocanalysis of multiple comparisons was 
performed with the Sidak P-value correction. ANOVA assumptions were assessed using the 
Shapiro-Wilk test for normality and Levene’s test for homogeneity of variances. Multivariate 
analyses of concentration data from 1H-NMR and DI-MS were performed using Metaboanalyst 
3.0, a free online analysis utility for metabolomics31; 32. Data were normalized to the sum and 
scaled by unit variance. To assess major variation in the dataset and to identify outliers, 
unsupervised principal component analysis (PCA) was performed. Outliers were defined as 









supervised partial least squares discriminant analysis (PLS-DA) was utilized. Variable 
importance in projection (VIP) plots listing the top 15 metabolites were generated for each PLS-
DA model. VIP scores estimate the relative importance of each metabolite in the projection of a 
PLS model, providing a quantitative parameter of a metabolite’s importance in distinguishing 
between two groups. Analyses were performed between th  two experimental groups at each 
time point. PLS-DA models were then validated using permutation testing (2000 iterations).  
Biomarker and Pathway Topology Analysis  
Data were analyzed using the Biomarker function in Metaboanalyst to determine which 
metabolite pairs would be best for developing predictive models for use as disease biomarkers. 
Predictive classification models were built using various combination pairs of the top 5 
metabolites, identified using least absolute shrinkage and selection operator (LASSO) regression 
analysis33. Predictive models were developed using a PLS-DA algorithm as the classification 
method and feature ranking method. The performance of predictive models was assessed using 
Monte-Carlo cross validation (MCCV) with balanced sub ampling, and the area under the 
receiver operating characteristic curve (AUROC) and predictive accuracy were calculated for 
each metabolite combination as measures of predictive ability. 
Topological pathway analysis was performed in MetaboAnalyst to identify the most 
perturbed biological pathways, as previously described34; 35. Briefly, the Rattus Norvegicus 
library was chosen, and the test for pathway enrichment analysis and relative-betweenness 











We accurately identified and quantified 58 metabolites using 1H NMR and 186 using DI-
MS. Some overlap was observed between the two platforms (22 metabolites) and as such, we 
took the average values for each individual metabolite measured using both analytical methods, 
yielding 222 unique metabolites (Supplemental Data, Table S1). 
Univariate Comparisons 
Based on two-Way ANOVA of raw data, 17 metabolites were found to be significantly 
different between ACLR and Control (P<0.05 after Sidak correction) at 72 hours (Table 1). At 4 
weeks, 8 metabolites had significantly different con entrations, and at 10 weeks, 3 metabolites 
were found to have significantly different concentrations (Table 1).  
Multivariate Modeling 
Unsupervised PCA modeling did not identify any signif cant outliers. The total 
percentage of explained variation by the first three principal components was 65.5% at 72 hrs, 
70.9% at 4 weeks, and 71.5% at 10 weeks. No notable separation was observed in any of the 
PCA models. (Supplemental Data, Figure S1). Subsequently, supervised PLS-DA modeling was 
applied, which yielded marked group separation betwe n Control and ACLR at 72 hrs (Fig 2A) 
and 4 weeks (Fig 2C), and modest separation at 10 weeks (Fig 2E). Despite this observed 
separation, given the relatively small sample size (n=6), these models were not found to be 
significant following cross validation using 2000 iterations of permutation testing (72 hrs: 
P=0.760; 4 weeks: P=0.999; 10 weeks: P=0.928). VIP plots of respective models at each time 
point indicate the top 15 most contributory metabolites responsible for group separation (Fig 2B, 
D, F). At 72 hrs, increases in the concentrations of glycine and 9-hexadecenoylcarnitine, and 









and ACLR (Fig 2B). Based on univariate analyses, there were no significant differences in the 
concentrations of glycine (Control: 195.7 µM ± 32.5, ACLR: 214.5 µM ± 20.2, P=0.201) or 9-
hexadecenoylcarnitine (Control: 25.8 nM ± 6.14, ACLR: 30.5 nM ± 2.42, P=0.182), but a 
significant difference in carnosine concentration was observed (Control: 2.56 µM ± 1.80, ACLR: 
0.452 µM ± 0.304, P=0.007). In addition to these three metabolites, fumaric acid (Control: 17.51 
µM ± 7.41, ACLR: 9.750 µM ± 4.20, P=0.023), isopropyl alcohol (Control: 49.56 µM ± 23.51, 
ACLR: 78.45 µM ± 26.07, P=0.043), and 3,5-Tetradecadiencarnitine (Control: 0.01 7 µM ± 
0.0023, ACLR: 0.0157 µM ± 0.0064, P=0.041) had significantly different absolute 
concentrations based on univariate analyses and were in the top-15 highest VIP scores (Fig 2B).  
At 4 weeks post-injury, the VIP plot demonstrates that increases in the concentrations of 
trans-2-dodecenoylcarnitine, acetic acid, and 9-decenoylcarnitine were the three most 
contributory features to group separation (Fig 2D). There were significant univariate differences 
in the concentrations of trans-2-dodecenoylcarnitine (Control: 0.216 µM ± 0.035, ACLR: 0.320 
µM ± 0.044, P=0.008) and 9-decenoylcarnitine (Control: 0.218 µM ± 0.031, ACLR: 0.313 µM ± 
0.041, P=0.012) but not in acetic acid concentration (Contrl: 73.43 µM ± 12.1, ACLR: 89.61 
µM ± 17.4, P=0.306). Furthermore, Linoelaidyl carnitine (Control: 0.025 µM ± 0.004, ACLR: 
0.014 µM ± 0.007, P 0.008), serotonin (Control: 3.460 µM ± 1.47, ACLR: 1.840 µM ± 0.470, 
P=0.006), and L-Palmitoylcarnitine (Control: 0.170 µM ± 0.046, ACLR: 0.116 µM ± 0.020, 
P=0.012) had significant differences in absolute concentrations and were in the top-15 highest 
VIP scores (Fig 2D).  
At 10 weeks, VIP plots indicate that a decrease in D-Mannose concentration and 
increases in hexanoylcarnitine and butyrylcarnitine concentrations were the three most 









difference in D-Mannose concentration between Control and ACLR (Control: 75.93 µM ± 26.4, 
ACLR: 31.98 µM ± 25.1, P=0.076) and significant differences in the concentrations of 
hexanoylcarnitine (Control: 0.129 µM ± 0.055, ACLR: 0.470 µM ± 0.322, P=0.020) and 
butyrylcarnitine (Control: 2.325 µM ± 1.30, ACLR: 6.9 5 µM ± 4.69, P=0.016). In addition, 
Hydroxypropionylcarnitine (Control: 9.00 nM ± 8.36, ACLR: 1.33 nM ± 1.75, P=0.024) had 
significantly different absolute concentration betwen Control and ACLR and were in the top-15 
highest VIP scores (Fig 2F) 
Predictive Biomarker Models 
Having established which metabolites had the greatest bsolute concentration differences 
and contributed most notably to group separation of multivariate models (i.e. highest VIP 
scores), we used LASSO regression to identify 5 metabolites at each time point, and predictive 
models were built to determine the predictive ability of combination pairs of the 5 identified 
metabolites as potential biomarkers of PTOA on et and progression (Table 2, Figure 3). At 72 
hours, Glycine, 9-Hexadecenoylcarnitine, Fumaric acid, Methionine sulfoxide, and PC(o-
24:0/18:3(6Z,9Z,12Z)) were selected for biomarker analysis. AUROC values of combination 
pairs ranged from 0.848 to 0.952, and predictive accuracies of these models following 100-fold 
cross validation ranged from 71.0% to 82.0% (Table 2). The combination of Glycine and 9-
Hexadecenoylcarnitine generated the model with the highest AUROC of 0.952 (95% CI 0.75 – 
1.00) (Figure 3A), and this model had a predictive accuracy of 76.8%. At 4 weeks, trans-2-
Dodecenoylcarnitine, 9-Decenoylcarnitine, Acetic acid, Serotonin, and Linoelaidyl carnitine 
were selected for biomarker analysis. AUROC values of metabolite pairs at 4 weeks ranged from 
0.770 – 0.998, and following 100-fold cross validaton, predictive accuracies ranged from 66.8% 









produced the model with the highest AUROC of 0.998 ( 5% CI 1.00 – 1.00) (Figure 3B), and 
this model had a predictive accuracy of 96.8%. At 10 weeks, Hydroxypropionylcarnitine, D-
Mannose, Formic acid, Hexanoylcarnitine, and Propionylcarnitine were selected as the top 5 
metabolites for biomarker analysis. Combinations of these 5 metabolites generated AUROC 
values ranging from 0.712 – 0.975, with predictive accuracies following 100-fold cross 
validation found to range from 65.8% - 87.8% (Table 2). The combination of 
Hydroxypropionylcarnitine and D-Mannose produced the model with the highest AUROC of 
0.975 (95% CI 0.50 – 1.00) (Figure 3C), and this combination had a predictive accuracy of 
87.8%.  
Pathway Analysis 
Topological pathway analysis revealed several perturbed biochemical pathways due to 
alterations in metabolite concentration after ACL injury (Table 3). At 72 hours, 12 pathways 
were significantly perturbed (P≤0.1). The most significantly-affected pathways at 72 hours were 
cyanoamino acid metabolism (P=0.017), methane metabolism (P=0.030), sphingolipid 
metabolism (P=0.031), histidine metabolism (P=0.033), and glutathione metabolism (P=0.033). 
At 4 weeks, Tryptophan metabolism (P=0.063) and β-Alanine metabolism (P=0.081) were 
significantly perturbed, and at 10 weeks, fructose and mannose metabolism (P=0.020) and amino 
sugar and nucleotide sugar metabolism (P=0.020) were significantly perturbed.  
Discussion 
Despite the increasing incidence of PTOA in both military and civilian populations36, the 
exact mechanisms connecting joint trauma to the onst and progression of joint degeneration are 
poorly understood. Evidence supporting the existence of underlying acute biologic phenomena at 









present study, we applied high-resolution 1H-NMR spectroscopy and DI-MS to measure 
metabolite concentrations in the serum of rats subjected to a validated, non-surgical ACL rupture 
protocol26. We found that several carnitine and tryptophan metabolites distinguished ACLR from 
Control rats, and AUROC analysis of the top two LASSO regression-identified metabolites at 
each time point demonstrated predictive accuracies of 76.8%, 96.8% and 87.8% at 72 hrs, 4 
weeks and 10 weeks, respectively. These results demonstrate that the combined 1H-NMR and 
DI-MS platforms are powerful techniques to identify biomarkers and potential biologic 
mechanisms underlying PTOA development. 
VIP plots from PLS-DA modeling demonstrated that increased glycine and 
hexadecenoylcarnitine concentrations, along with decreased carnosine concentrations, were most 
contributory to distinguishing ACLR rats from Control rats at 72 hours. At 4 weeks, increased 
concentrations of trans-2-dodecenoylcarnitine, acetic acid, and 9-decenoylcarnitine were the top 
three features, and at 10 weeks, decreased D-mannose and increased hexanoylcarnitine and 
butyrylcarnitine concentrations were most contributory to group separation. Mickiewicz et al 
employed 1H-NMR to characterize metabolites in synovial fluid two weeks after idealized ACL 
reconstruction procedure in sheep22. They found higher synovial fluid concentrations of 
isobutyrate and glucose in sheep that had undergone ACL reconstruction, while hydroxyproline, 
asparagine, serine, and uridine concentrations were low r. Similarly, we found that serum 
concentrations of L-serine and isobutyrate were increased in rats with an ACL rupture at the 72-
hour time point, though univariate analysis did not demonstrate significant concentration 
differences of these metabolites. Further, VIP analysis demonstrated that isobutyrate was among 
the key markers contributing to separation between th  ACLR and Control group at the 72-hour 









approach was used to measure metabolite concentratio s in synovial fluid from patients with 
chronic knee osteoarthritis and healthy controls23. They identified the 11 metabolites most 
responsible for OPLS-DA separation between OA and Control synovial fluid, and our analysis 
identified one serum metabolite in common with the synovial fluid results of Mickiewicz et al: 
the medium-chain acylcarnitine, hexanoylcarnitine.  
At each time point, the serum concentration of several acylcarnitine species contributed 
significantly to PLS-DA separation. Acylcarnitines are fatty acid esters of L-carnitine which play 
important roles in energy production by promoting the entry of long chain fatty acids into the 
mitochondrion via the carnitine shuttle. Univariate analysis showed that free carnitine (L-
carnitine) was significantly decreased in ACLR animals, while VIP analysis demonstrated that a 
total of 15 acylcarnitine species contributed substantially to model separation. Eight of these 
acylcarnitine species had significant univariate concentration differences between ACLR and 
Control, with five metabolites exhibiting increased and three metabolites displaying decreased 
concentrations. Low circulating levels of free carnitine and acylcarnitine species have been 
implicated in several immune/inflammatory conditions, including systemic lupus erythematous 
(SLE)37 and rheumatoid arthritis (RA)38. Prior to definitive clinical onset of RA, Surowiec t al 
observed a decrease in plasma acylcarnitines when compared to healthy controls39. Incomplete 
β-oxidation is implicated in the accumulation of esterified carnitine species, which may promote 
inflammation through the NF-κΒ pathway37.  Zhang et al defined OA phenotypes via 
metabolomic analyses and found that one specific phenotype was defined by differential 
expression of acylcarnitines40, though it was unclear if this was a post-traumatic OA phenotype. 
Adams, et al. demonstrated that acylcarnitine species were significantly increased in the 









evidence of OA that were undergoing surgery due soft tissue injury. Our present study indicates 
a strong influence from trans-2-docecenoylcarnitine at 4 weeks, with a 1.48-fold change relative 
to Control (P=0.008), the highest VIP value in PLS-DA modeling, and a 96.8% predictive 
accuracy (AUROC = 0.998, 95% CI 0.97-1.00) when paired with linoelaidyl carnitine in 
predictive modeling. These results and findings from the aforementioned studies indicate that 
free- and esterified carnitine metabolites may play a role in OA/PTOA development.  
Topological pathway analysis demonstrated several perturbed pathways due to ACLR 
(Table 3). One potentially important perturbed pathway in the context of arthritis was tryptophan 
metabolism. Several tryptophan metabolites were significantly different between ACLR and 
Controls at 72 hrs (decreased L-aspartic acid, 1-phenylethylamine, and serotonin concentrations). 
At 4 weeks, a decrease in L-kynurenine, serotonin, and L-aspartic acid were top VIP features, 
and at 10 weeks, an increase in 1-phenylethylamine was a top VIP feature. Kang, et al. 
demonstrated that synovial fluid from patients with RA showed significantly lower 
concentrations of tryptophan metabolites42, including kynurenine, indoelactic acid, N’-
Formylkynurenine and indoleacetaldehyde when compared to synovial fluid from OA patients. 
Kynurenine is an endogenous ligand for the aryl hydrocarbon receptor (AHR), and binding of 
AHR by kynurenine leads to production of Tregs and suppression of IL-17-producing Th cell 
populations43; 44. Further, Chen et al demonstrated that increasing kynurenine levels via 
indoleamine 2,3-dioxygenase (IDO)-targeted gene therapy promoted the resolution of collagen-
induced arthritis45, primarily by apoptosis of T-cells and reduction i synovial IL-17. We 
previously demonstrated that our ACL injury model leads to acutely-increased IL-17 expression 
in synovium27. Given the presently-demonstrated reduction in tryptophan metabolites that could 









favored in the acute period after injury. Furthermoe, the tryptophan metabolite serotonin has 
been closely linked with bone mineral density in the setting of osteoporosis46 and with IL-17-
associated osteoclastogenesis in autoimmune arthritis47, ndicating that serotonin may play a role 
in the subchondral and epiphyseal bone remodeling we have observed following ACL rupture in 
this model 14.  
In addition to metabolites involved in carnitine and tryptophan metabolism, several other 
key metabolites contributed to the observed PLS-DA separation. At 72 hours, glycine had the 
highest VIP score and was involved in the significant perturbation of several pathways (Table 3). 
Glycine has been recently implicated in muscle fibrosis in RA patients48 and as an amino acid 
crucial for collagen synthesis, it may be linked to acute tissue remodeling in our model, but 
further experimentation is necessary to elucidate its precise role in PTOA. At 72 hours, carnosine 
had the third-highest VIP rank and had significantly lower univariate concentrations in ACLR 
compared to Control (P = 0.007). Ponist et al recently demonstrated that oral carnosine reduced 
edema in the paws of carrageenan-treated rats in adjuvant arthritis and further demonstrated 
reduced oxidative stress in primary culture of articular chondrocytes49 – these findings may be an 
indication that reduced carnosine observed in our data is involved in post-injury inflammation. In 
addition, D-mannose was a strong contributor to model separation at 10 weeks, with a VIP value 
near 2.8 and a lower univariate concentration difference of trending significance (P = 0.076). 
Furthermore, D-mannose was a key metabolite in the significant perturbation of fructose and 
mannose metabolism (P = 0.020) and amino sugar and nucleotide sugar metabolism (P = 0.020). 
Mannose is a monosaccharide involved in protein N-glycosylation, which is integral to several 
physiologic functions including lectin-mediated cell-cell interactions. One hypothesis is that 









immune cell trafficking to the injured joint, which we have observed in this model 27. Urita et al 
described decreased concentrations of N-glycan species in both human and murine osteoarthritic 
articular cartilage and demonstrated a correlation between high mannose N-glycans and 
chondrocyte production of matrix-degrading enzymes MMP-13 and ADAMTS-5 in response to 
interleukin-1α stimulation.50 Additional investigation into the roles of glycine, carnosine, and D-
mannose in the onset and progression of ACL rupture-induced PTOA is warranted.  
Our study is not without limitations. Our findings are limited by a small sample size 
(n=6), and our PLS-DA models were not found to be significant. Nonetheless, as a preliminary 
investigation of the serum metabolome after ACL injury, we found several significant univariate 
differences, significantly-perturbed pathways, and high AUROC and predictive accuracy values 
from predictive modeling. Another limitation is the lack of concomitant analysis of local joint 
tissue or synovial fluid – additional metabolic profiling of synovial fluid, synovial membrane, 
cartilage and subchondral bone would provide a greate  understanding of local biochemical 
changes following ACL rupture. Although we performed a cross-sectional experiment to assess 
three distinct time points, we did not perform multivariate modeling as a function of time, which 
could characterize metabolites involved in disease progression. Future studies are planned to 
undertake more powered studies involving longitudinal multivariate analyses. Lastly,further 
characterization is warranted to determine whether  pattern of expression of the identified 
metabolites aids in distinguishing between PTOA, idiopathic osteoarthritis, and inflammatory 
arthropathies, which the present study did not address.  
To our knowledge, this is the first high-resolution metabolomics characterization of ACL 
rupture-induced PTOA utilizing both 1H NMR and DI-MS. Univariate and multivariate analyses 









metabolites differentiate Control and ACLR rats, and these factors may be regulators of the acute 
and intermediate phases of PTOA. Altered serum levels of carnitine species have been associated 
with several conditions involving immune dysregulation, including RA38. Reduced serum 
concentration of tryptophan metabolites may further support immune dysregulation in animals 
with ACL rupture, as decreased levels of tryptophan metabolites are frequently observed in 
inflammatory arthropathies37; 38 and are associated with increased pro-inflammatory cytokine 
production51 and decreased levels of immunomodulating Tregs
43. Glycine, carnosine, and D-
mannose were strong metabolites differentiating ACLR from Control rats, and each has been 
associated with immune and inflammatory conditions48-50. The findings from this preliminary 
investigation indicate a role of immune and inflammatory processes in the response to injury and 




The authors have no relevant conflicts of interest lated to the topic of the work.  
References 
1. Little CB, Hunter DJ. 2013. Post-traumatic osteoarthritis: from mouse models to clinical trials. 
Nat Rev Rheumatol 9:485-497. 
2. Lohmander L, Östenberg A, Englund M, et al. 2004. High prevalence of knee osteoarthritis, pain, 
and functional limitations in female soccer players twelve years after anterior cruciate ligament 
injury. Arthritis Rheum 50:3145-3152. 
3. Svoboda SJ. 2014. ACL injury and posttraumatic osteoarthritis. Clin Sports Med 33:633-640. 
4. Von Porat A, Roos E, Roos H. 2004. High prevalence of osteoarthritis 14 years after an anterior 
cruciate ligament tear in male soccer players: a study of radiographic and patient relevant 
outcomes. Ann Rheum Dis 63:269-273. 
5. Heard BJ, Solbak NM, Achari Y, et al. 2013. Changes of early post-traumatic osteoarthritis in an 
ovine model of simulated ACL reconstruction are associated with transient acute post-injury 









6. O'Brien EJ, Beveridge JE, Huebner KD, et al. 2013. Osteoarthritis develops in the operated joint 
of an ovine model following ACL reconstruction with immediate anatomic reattachment of the 
native ACL. J Orthop Res 31:35-43. 
7. Tourville TW, Johnson RJ, Slauterbeck JR, et al. 2013. The relationship between synovial fluid 
ARGS, cytokines, MMPs & TIMPs following acute ACL injury. Osteoarthritis Cartilage 21:S75. 
8. Tang Z, Yang L, Zhang J, et al. 2009. Coordinated expression of MMPs and TIMPs in rat knee 
intra-articular tissues after ACL injury. Connect Tissue Res 50:315-322. 
9. Hayward A, Deehan D, Aspden R, et al. 2011. Analysis of sequential cytokine release after ACL 
reconstruction. Knee Surg Sports Traumatol Arthrosc 19:1709-1715. 
10. Wu Y, Yang R, Chen P, et al. 2009. The profile of MMP and TIMP in injured rat ACL. Mol Cell 
Biomech 7:115-1124. 
11. Friel NA, Chu CR. 2013. The role of ACL injury in the development of posttraumatic knee 
osteoarthritis. Clin Sports Med 32:1-12. 
12. Lotz MK. 2010. New developments in osteoarthritis: posttraumatic osteoarthritis: pathogenesis 
and pharmacological treatment options. Arthritis research & therapy 12:211. 
13. Scanzello CR, Goldring SR. 2012. The role of synovitis in osteoarthritis pathogenesis. Bone 
51:249-257. 
14. Maerz T, Kurdziel M, Newton M, et al. 2016. Subchondral and epiphyseal bone remodeling 
following surgical transection and noninvasive rupture of the anterior cruciate ligament as 
models of post-traumatic osteoarthritis. Osteoarthritis Cartilage 24:698-708. 
15. Ramme A, Lendhey M, Raya J, et al. 2016. A novel rat model for subchondral microdamage in 
acute knee injury: a potential mechanism in post-traumatic osteoarthritis. Osteoarthritis 
Cartilage 24:1776-1785. 
16. Anderson DD, Chubinskaya S, Guilak F, et al. 2011. Post-traumatic osteoarthritis: Improved 
understanding and opportunities for early intervention. J Orthop Res 29:802-809. 
17. Maerz T, Newton M, Kurdziel M, et al. 2016. Articular cartilage degeneration following anterior 
cruciate ligament injury: a comparison of surgical transection and noninvasive rupture as 
preclinical models of post-traumatic osteoarthritis. Osteoarthritis Cartilage 24:1918-1927. 
18. Buck R, Wyman B, Le Graverand M-PH, et al. 2010. Osteoarthritis may not be a one-way-road of 
cartilage loss–comparison of spatial patterns of cartilage change between osteoarthritic and 
healthy knees. Osteoarthritis Cartilage 18:329-335. 
19. Eckstein F, Wirth W, Lohmander L, et al. 2015. Five-Year Followup of Knee Joint Cartilage 
Thickness Changes After Acute Rupture of the Anterior Cruciate Ligament. Arthritis Rheum 
67:152-161. 
20. Lotz M, Martel-Pelletier J, Christiansen 0000-0002-0105-6458 C, et al. 2013. Value of biomarkers 
in osteoarthritis: current status and perspectives. Ann Rheum Dis:annrheumdis-2013-203726. 
21. Beckonert O, Keun HC, Ebbels TM, et al. 2007. Metabolic profiling, metabolomic and 
metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts. 
Nat Protoc 2:2692-2703. 
22. Mickiewicz B, Heard BJ, Chau JK, et al. 2015. Metabolic profiling of synovial fluid in a unilateral 
ovine model of anterior cruciate ligament reconstruction of the knee suggests biomarkers for 
early osteoarthritis. J Orthop Res 33:71-77. 
23. Mickiewicz B, Kelly JJ, Ludwig TE, et al. 2015. Metabolic analysis of knee synovial fluid as a 
potential diagnostic approach for osteoarthritis. J Orthop Res 33:1631-1638. 
24. Zhang W, Sun G, Likhodii S, et al. 2016. Metabolomic analysis of human plasma reveals that 
arginine is depleted in knee osteoarthritis patients. Osteoarthritis Cartilage 24:827-834. 
25. Adams Jr SB, Setton LA, Nettles DL. 2013. The role of metabolomics in osteoarthritis research. J 









26. Maerz T, Kurdziel MD, Davidson AA, et al. 2015. Biomechanical Characterization of a Model of 
Noninvasive, Traumatic Anterior Cruciate Ligament Injury in the Rat. Ann Biomed Eng:1-10. 
27. Maerz T, Fleischer M, Newton MD, et al. 2017. Acute mobilization and migration of bone 
marrow-derived stem cells following anterior cruciate ligament rupture. Osteoarthritis Cartilage 
25:1335-1344. 
28. Mercier P, Lewis M, Chang D, et al. 2011. Towards automatic metabolomic profiling of high-
resolution one-dimensional proton NMR spectra. J Biomol NMR 49:307-323. 
29. Ravanbakhsh S, Liu P, Bjordahl TC, et al. 2015. Accurate, fully-automated NMR spectral profiling 
for metabolomics. PLoS One 10:e0124219. 
30. Pan X, Nasaruddin MB, Elliott CT, et al. 2016. Alzheimer's disease-like pathology has transient 
effects on the brain and blood metabolome. Neurobiol Aging 38:151-163. 
31. Xia J, Mandal R, Sinelnikov IV, et al. 2012. MetaboAnalyst 2.0--a comprehensive server for 
metabolomic data analysis. Nucleic Acids Res 40:W127-133. 
32. Xia J, Sinelnikov IV, Han B, et al. 2015. MetaboAnalyst 3.0-making metabolomics more 
meaningful. Nucleic Acids Res 43:W251-W257. 
33. Tibshirani R. 1996. Regression shrinkage and selection via the lasso. J R Stat Soc Series B Stat 
Methodol:267-288. 
34. Graham SF, Kumar P, Bahado-Singh RO, et al. 2016. Novel metabolite biomarkers of 
Huntington’s disease (HD) as detected by high resolution mass spectrometry. J Proteome Res. 
35. Graham SFK, P.K.; Bjorndahl, B.; Han, B.; Yilmaz, A.; Sherman, E.; Bahado-Singh, R.O.; Wishart, 
D.; Mann, D.; Green, B.D. 2016. Metabolic signatures of Huntington’s disease (HD): 1H NMR 
analysis of the polar metabolome in post mortem human brain. Biochim Biophys Acta. 
36. Showery JE, Kusnezov NA, Dunn JC, et al. 2016. The Rising Incidence of Degenerative and 
Posttraumatic Osteoarthritis of the Knee in the United States Military. J Arthroplasty 31:2108-
2114. 
37. Wu T, Xie C, Han J, et al. 2012. Metabolic disturbances associated with systemic lupus 
erythematosus. PLoS One 7:e37210. 
38. van Wietmarschen HA, Dai W, van der Kooij AJ, et al. 2012. Characterization of rheumatoid 
arthritis subtypes using symptom profiles, clinical chemistry and metabolomics measurements. 
PLoS One 7:e44331. 
39. Surowiec I, Arlestig L, Rantapaa-Dahlqvist S, et al. 2016. Metabolite and Lipid Profiling of 
Biobank Plasma Samples Collected Prior to Onset of Rheumatoid Arthritis. PLoS One 
11:e0164196. 
40. Zhang W, Likhodii S, Zhang Y, et al. 2014. Classification of osteoarthritis phenotypes by 
metabolomics analysis. BMJ Open 4:e006286. 
41. Adams SB, Jr., Setton LA, Kensicki E, et al. 2012. Global metabolic profiling of human 
osteoarthritic synovium. Osteoarthritis Cartilage 20:64-67. 
42. Kang KY, Lee SH, Jung SM, et al. 2015. Downregulation of Tryptophan-related Metabolomic 
Profile in Rheumatoid Arthritis Synovial Fluid. J Rheumatol 42:2003-2011. 
43. Mezrich JD, Fechner JH, Zhang X, et al. 2010. An interaction between kynurenine and the aryl 
hydrocarbon receptor can generate regulatory T cells. J Immunol 185:3190-3198. 
44. Nguyen NT, Nakahama T, Le DH, et al. 2014. Aryl hydrocarbon receptor and kynurenine: recent 
advances in autoimmune disease research. Front Immunol 5:551. 
45. Chen SY, Wu CL, Lai MD, et al. 2011. Amelioration of rat collagen-induced arthritis through CD4+ 
T cells apoptosis and synovial interleukin-17 reduction by indoleamine 2,3-dioxygenase gene 









46. Karasik D, Cheung CL, Zhou Y, et al. 2012. Genome-wide association of an integrated 
osteoporosis-related phenotype: is there evidence for pleiotropic genes? J Bone Miner Res 
27:319-330. 
47. Chabbi-Achengli Y, Coman T, Collet C, et al. 2016. Serotonin Is Involved in Autoimmune Arthritis 
through Th17 Immunity and Bone Resorption. Am J Pathol 186:927-937. 
48. Huffman KM, Jessee R, Andonian B, et al. 2017. Molecular alterations in skeletal muscle in 
rheumatoid arthritis are related to disease activity, physical inactivity, and disability. Arthritis 
Res Ther 19:12. 
49. Ponist S, Drafi F, Kuncirova V, et al. 2016. Effect of Carnosine in Experimental Arthritis and on 
Primary Culture Chondrocytes. Oxid Med Cell Longev 2016:8470589. 
50. Urita A, Matsuhashi T, Onodera T, et al. 2011. Alterations of high-mannose type N-glycosylation 
in human and mouse osteoarthritis cartilage. Arthritis Rheum 63:3428-3438. 
51. Bertazzo A, Punzi L, Bertazzolo N, et al. 1999. Tryptophan catabolism in synovial fluid of various 





Figure 1. A representative 1D 1H NMR spectrum of serum used in this study. (A) Aliphatic 
region; (B) Aromatic region. 1. Histidine , 2. 1-methylhistidine, 3. Formate, 4. Tyrosine, 5. 
Phenylalanine, 6. Urea, 7. Hippurate, 8. Tryptophan, 9. 3-Methylhistidine, 10. Xanthine, 11. 
Fumarate, 12. 2-Hydroxybutyrate, 13.3-Hydroxybutyrate, 14. Leucine, 15. Isopropanol, 16. 
Isobutyrate, 17. Valine, 18. Propylene glycol, 19. Methanol, 20. Dimethyl sulfone, 21. Acetone, 
22. 3-Hydroxyisovalerate, 23. Isovalerate, 24. Acetate, 25. Betaine, 26. Acetoacetate, 27. 
Carnitine, 28 Lactate, 29. Creatine, 30. Creatinine, 31. Dimethylamine, 32. Dimethylglycine, 33. 
Citratel, 34. Choline, 35. Ethanol, 36. Glucose, 37. Glycerol, 38. Glycine, 39. Glutamate, 40. 
Alanine, 41. Proline, 42. Threonine, 43. Asparagine, 44. Mannose, 45. Isoleucine, 46. Lysine, 47. 
Serine, 48. Methionine, 49. Malonate, 50. Pyruvate, 51. Succinate, 52.Aspartate , 53. Myo-










Figure 2 – PLS-DA scores plots (A, C, E) and corresponding VIP plots (B, D, F) of Control and 
ACLR rats at 72 hours, 4 weeks, and 10 weeks. Shaded regions on PLS-DA plots correspond to 
the 95% confidence interval region. VIP plots rank metabolites by VIP score, a quantitative 
parameter of a given metabolite’s importance in observed group separation (i.e. projection of 
the PLS-DA model).  
Figure 3 – ROC curves of metabolite pairs used for predictive modeling at 72 hours (A), 4 weeks 
(B), and 10 weeks (C).  
 
Table Legends: 
Table 1 – Metabolites with significantly different concentrations between Control and ACLR 
based on univariate Two-Way ANOVA at 72 hours, 4 weeks, and 10 weeks.  
Table 2 – Area under the receiver operating characteristic curve (AUROC) with 95% CIs and 
Predictive Accuracy (PA) of Metabolite Pairs used to develop predictive biomarker models. 
Table 3 – Results of pathway topology analysis indicating perturbed biochemical pathways been 
Control and ACLR rats.  
 
Table 1 – Metabolites with significantly different concentrations between Control and ACLR 






(µM ± SD) 
ACLR 





L-Aspartic acid 102.73 ± 41.99 62.90 ± 21.58 0.612 0.002 
C5-DC/C6-OH 0.0238 ± 7.33E-3 0.013 ± 0.007 0.542 0.005 
72s 
hours 









1-Phenylethylamine 6.517 ± 5.152 2.353 ± 3.687 0.361 0.009 
N-Acetylornithine 3.063 ± 0.697 2.100 ± 0.511 0.685 0.011 
Succinic acid 610.23 ± 396.11 300.70 ± 129.85 0.493 0.011 
C16-OH 0.00783 ± 4.08E-4 0.0130 ± 0.007 1.639 0.016 
Formic acid 87.50 ± 38.71 48.05 ± 18.87 0.549 0.021 
Fumaric acid 17.51 ± 7.413 9.750 ± 4.207 0.556 0.023 
C5-OH/C3-DC-M 0.0972 ± 0.0253 0.0730 ± 0.0160 0.751 0.023 
Serotonin 2.322 ± 1.324 1.023 ± 0.442 0.441 0.031 
L-Carnitine 48.20 ± 8.768 38.16 ± 9.988 0.792 0.034 
Spermidine 77.15 ± 117.10 189.20 ± 180.15 2.451 0.038 
3,5-Tetradecadiencarnitine 0.0107 ± 2.34E-3 0.0157 ± 6.41E-3 1.468 0.041 
Isopropyl alcohol 49.56 ± 23.51 78.45 ± 26.07 1.582 0.043 
H1 12811 ± 2613 10132 ± 2479.0 0.791 0.048 
 
3-Nitrotyrosine 0.831 ± 0.229 0.680 ± 0.209 0.818 0.048 
Serotonin 3.460 ± 1.470 1.840 ± 0.470 0.531 0.006 
Linoelaidyl carnitine 0.0250 ± 0.004 0.0140 ± 0.007 0.586 0.008 
trans-2-Dodecenoylcarnitine 0.216 ± 0.035 0.3200 ± 0.044 1.479 0.008 
L-Palmitoylcarnitine 0.170 ± 0.046 0.116 ± 0.020 0.683 0.012 
Stearoylcarnitine 0.100 ± 0.050 0.063 ± 0.009 0.636 0.013 
Oleoylcarnitine 0.100 ± 0.0220 0.0707 ± 0.0143 0.705 0.027 





PC16:0/16:0 20.13 ± 16.48 10.68 ± 2.017 0.531 0.034 
Butyrylcarnitine 2.320 ± 1.30 6.960 ± 0.32 2.994 0.016 
Hexanoylcarnitine 0.129 ± 0.055 0.470 ± 0.32 3.650 0.020 
10 weeks 
 
Hydroxypropionylcarnitine 9.00E-3 ± 8.36E-3 1.33E-3 ±1.75E-3 0.176 0.024 
 
 
Table 2 – Area under the receiver operating characteristic curve (AUROC) with 95% CIs and 
Predictive Accuracy (PA) of Metabolite Pairs used to develop predictive biomarker models. 









72 hours Glycine 9-Hexadecenoyl-carnitine 0.952 (0.75-1.00) 76.8% 
  Fumaric acid 0.912 (0.75-1.00) 82.0% 
  Methionine sulfoxide 0.908 (0.50-1.00) 70.2% 
  PC(o-24:0/18:3(6Z,9Z,12Z)) 0.925 (0.62-1.00) 77.8% 
 9-Hexanedecenoyl-carnitine Fumaric acid 0.895 (0.50-1.00) 78.8% 
  Methionine sulfoxide 0.938 (0.50-1.00) 76.8% 
  PC(o-24:0/18:3(6Z,9Z,12Z)) 0.925 (0.50-1.00) 82.0% 
 Fumaric acid Methionine sulfoxide 0.860 (0.50-1.00) 71.0% 
  PC(o-24:0/18:3(6Z,9Z,12Z)) 0.848 (0.50-1.00) 70.2% 
 Methionine sulfoxide PC(o-24:0/18:3(6Z,9Z,12Z)) 0.942 (0.75-1.00) 81.8% 
4 weeks trans-2-Dodecenoylcarnitine 9-Decenoylcarnitine 0.828 (0.50-1.00) 66.8% 
  Acetic acid 0.910 (0.25-1.00) 82.5% 
  Serotonin 0.998 (1.00-1.00) 93.0% 
  Linoelaidyl carnitine 0.998 (1.00-1.00) 96.8% 
 9-Decenoylcarnitine Acetic acid 0.830 (0.25-1.00) 79.0% 
  Serotonin 0.998 (1.00-1.00) 94.5% 
  Linoelaidyl carnitine 0.962 (0.50-1.00) 91.0% 
 Acetic acid Serotonin 0.938 (0.62-1.00) 83.2% 
  Linoelaidyl carnitine 0.912 (0.50-1.00) 82.0% 
 Serotonin Linoelaidyl carnitine 0.770 (0.25-1.00) 66.2% 
10 weeks Hydroxypropionylcarnitine D-Mannose 0.965 (0.50-1.00) 87.8% 
  Formic acid 0.875 (0.50-1.00) 78.0% 
  Hexanoylcarnitine 0.900 (0.50-1.00) 77.5% 
  Propionylcarnitine 0.910 (0.50-1.00) 78.2% 
 D-Mannose Formic acid 0.712 (0.25-1.00) 69.2% 
  Hexanoylcarnitine 0.840 (0.50-1.00) 75.7% 
  Propionylcarnitine 0.840 (0.50-1.00) 72.0% 
 Formic acid Hexanoylcarnitine 0.740 (0.25-1.00) 67.0% 
  Propionylcarnitine 0.745 (0.12-1.00) 65.8% 












Table 3 – Results of pathway topology analysis indicating perturbed biochemical pathways been 
Control and ACLR rats.  
Time Point Pathway(s) Total 
Compounds 
Hits (number of hits) P Value 
72 hours Cyanoamino acid metabolism 6 Glycine, L-Serine (2) 0.017 
 Methane metabolism 9 Glycine, Methanol, Formic acid, L-Serine (4) 0.030 
 Sphingolipid metabolism 21 SM, L-Serine (2) 0.031 
 Histidine metabolism 15 L-Glutamic acid, L-Histidine, Histamine, 
Carnosine, L-Aspartic acid, 1-Methylhistidine (6) 
0.033 
 Glutathione metabolism 26 L-Glutamic acid, Glycine, Pyroglutamic acid, 
Ornithine, Putrescine, Spermidine, Spermine (7) 
0.033 
 Porphyrin and chlorophyll 
metabolism 
27 Glycine, L-Glutamic acid (2) 0.037 
     
 Primary bile acid biosynthesis 46 Glycine, Taurine (2) 0.038 
 Nitrogen metabolism 9 L-Glutamic acid, L-Glutamine, L-Histidine, 
Glycine (4) 
0.053 
 Propanoate metabolism 20 Succinic acid, 2-Hydroxybutyric acid (2) 0.063 
 Purine metabolism 68 Xanthine, L-Glutamine, Urea (3) 0.075 
 Arginine and proline metabolism 44 L-Glutamine, Ornithine, Citrulline, L-Aspartic 
acid, L-Arginine, L-Glutamic acid, N-
Acetylornithine, L-Proline, Hydroxyproline, 
Creatine, Putrescine, Spermidine, Fumaric acid, 
Urea, Spermine (15) 
0.075 
 Glycine, serine, and threonine 
metabolism 
32 L-Serine, Choline, Betaine, Dimethylglycine, 
Glycine, Sarcosine, L-Threonine, Creatine, 
Pyruvic acid (9) 
0.087 
4 weeks Tryptophan metabolism 41 L-Tryptophan, Serotonin, L-Kynurenine (3) 0.063 
 ß-Alanine metabolism 19 L-Aspartic acid, Spermidine, Spermine (3) 0.081 
10 weeks Fructose and mannose metabolism 19 D-Mannose (1) 0.020 
 Amino sugar and nucleotide sugar 
metabolism 





























Figure 3 - ROC composite  . 
 
